{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:29:32Z","timestamp":1792690172417,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bcp.2021.114423","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T03:50:25Z","timestamp":1611028225000},"page":"114423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Activation of the tumor suppressive Hippo pathway by triptonide as a new strategy to potently inhibit aggressive melanoma cell metastasis"],"prefix":"10.1016","volume":"185","author":[{"given":"Shijie","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quansheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2021.114423_b0005","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1539614","article-title":"Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity","volume":"8","author":"Kokolus","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2021.114423_b0010","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bcp.2021.114423_b0015","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","article-title":"Immunotherapy of melanoma: facts and hopes","volume":"25","author":"Weiss","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2021.114423_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010223","article-title":"Anti-PD-1 and novel combinations in the treatment of melanoma-an update","volume":"9","author":"Gellrich","year":"2020","journal-title":"J. Clin. Med."},{"issue":"125","key":"10.1016\/j.bcp.2021.114423_b0025","first-page":"114","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials. European journal of cancer (Oxford","volume":"2020","author":"Hauschild","year":"1990","journal-title":"England"},{"key":"10.1016\/j.bcp.2021.114423_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218160","article-title":"Proteomic profiling of archived tissue of primary melanoma identifies proteins associated with metastasis","volume":"21","author":"Shapanis","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2021.114423_b0035","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1007\/s12325-020-01430-x","article-title":"Patients with BRAF-mutant advanced\/metastatic melanoma: original research on the treatment reality in germany and austria in the era of choice","volume":"37","author":"Haferkamp","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bcp.2021.114423_b0040","first-page":"163","article-title":"Melanoma development: current knowledge on melanoma pathogenesis","volume":"27","author":"Lugovi\u0107-Mihi\u0107","year":"2019","journal-title":"Acta dermatovenerologica Croatica"},{"key":"10.1016\/j.bcp.2021.114423_b0045","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1177\/1535370218820287","article-title":"The great escape: how metastases of melanoma, and other carcinomas, avoid elimination","volume":"243","author":"Wells","year":"2018","journal-title":"Exp. Biol. Med. (Maywood, NJ)."},{"key":"10.1016\/j.bcp.2021.114423_b0050","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/febs.14040","article-title":"Targeting invasive properties of melanoma cells","volume":"284","author":"Arozarena","year":"2017","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2021.114423_b0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10555-017-9657-1","article-title":"The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies","volume":"36","author":"Kunz","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bcp.2021.114423_b0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.critrevonc.2018.11.002","article-title":"Advanced stage melanoma therapies: detailing the present and exploring the future","volume":"133","author":"Luther","year":"2019","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.bcp.2021.114423_b0065","doi-asserted-by":"crossref","unstructured":"A. Khunger, Z.S. Buchwald, M. Lowe, M.K. Khan, K.A. Delman, A.A. Tarhini, Neoadjuvant therapy of locally\/regionally advanced melanoma, Therap. Adv. Med. Oncol. 11 (2019) 1758835919866959.","DOI":"10.1177\/1758835919866959"},{"key":"10.1016\/j.bcp.2021.114423_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-019-00475-1","article-title":"Biomarkers predictive of survival and response to immune checkpoint inhibitors in melanoma","volume":"21","author":"Rizk","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.bcp.2021.114423_b0075","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/exd.12535","article-title":"Cell elasticity is an important indicator of the metastatic phenotype of melanoma cells","volume":"23","author":"Sarna","year":"2014","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bcp.2021.114423_b0080","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/exd.12618","article-title":"The role of melanin pigment in melanoma","volume":"24","author":"Slominski","year":"2015","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bcp.2021.114423_b0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.abb.2014.06.030","article-title":"The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1alpha expression and HIF-dependent attendant pathways","volume":"563","author":"Slominski","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2021.114423_b0090","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/ptr.6273","article-title":"HIF-1alpha\/VEGF signaling-mediated epithelial-mesenchymal transition and angiogenesis is critically involved in anti-metastasis effect of luteolin in melanoma cells","volume":"33","author":"Li","year":"2019","journal-title":"Phytother. Res."},{"key":"10.1016\/j.bcp.2021.114423_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176129","article-title":"Elucidation of melanogenesis cascade for identifying pathophysiology and therapeutic approach of pigmentary disorders and melanoma","volume":"21","author":"Hida","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2021.114423_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249631","article-title":"Suppression of Pax3-MITF-M axis protects from UVB-induced skin pigmentation by tetrahydroquinoline carboxamide","volume":"21","author":"Choi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2021.114423_b0105","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.mayocp.2014.02.009","article-title":"Melanoma resistance: a bright future for academicians and a challenge for patient advocates","volume":"89","author":"Slominski","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bcp.2021.114423_b0110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.mayocp.2014.02.002","article-title":"Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma","volume":"89","author":"Shah","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bcp.2021.114423_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000341","article-title":"Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma","volume":"8","author":"Klemen","year":"2020","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.bcp.2021.114423_b0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.12788\/j.sder.2018.028","article-title":"Immunotherapy for melanoma","volume":"37","author":"Cuevas","year":"2018","journal-title":"Semin. Cutan. Med. Surg."},{"key":"10.1016\/j.bcp.2021.114423_b0125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jid.2019.08.002","article-title":"The evolution of melanoma \u2013 moving beyond binary models of genetic progression","volume":"140","author":"Zeng","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2021.114423_b0130","first-page":"127","article-title":"Prioritization and comprehensive analysis of genes associated with melanoma","volume":"18","author":"Feng","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2021.114423_b0135","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1101\/gad.329771.119","article-title":"Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities","volume":"33","author":"Rambow","year":"2019","journal-title":"Genes Dev."},{"key":"10.1016\/j.bcp.2021.114423_b0140","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201900162","article-title":"YAP\/TAZ: drivers of tumor growth, metastasis, and resistance to therapy","volume":"42","author":"Thompson","year":"2020","journal-title":"BioEssays"},{"key":"10.1016\/j.bcp.2021.114423_b0145","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature11452","article-title":"Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila","volume":"490","author":"Ohsawa","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114423_b0150","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nature15382","article-title":"Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer","volume":"526","author":"Gregorieff","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114423_b0155","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature20829","article-title":"The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ER\u03b1","volume":"541","author":"Britschgi","year":"2017","journal-title":"Nature"},{"issue":"321\u201337","key":"10.1016\/j.bcp.2021.114423_b0160","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2021.114423_b0165","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41568-020-0240-7","article-title":"A census of pathway maps in cancer systems biology","volume":"20","author":"Kuenzi","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2021.114423_b0170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fmolb.2019.00157","article-title":"Hippo signaling-mediated mechanotransduction in cell movement and cancer metastasis","volume":"6","author":"Chang","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bcp.2021.114423_b0175","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/s41388-018-0649-6","article-title":"The complex entanglement of Hippo-Yap\/Taz signaling in tumor immunity","volume":"38","author":"White","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2021.114423_b0180","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1074\/jbc.RA117.000923","article-title":"Salvador has an extended SARAH domain that mediates binding to Hippo kinase","volume":"293","author":"Cairns","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114423_b0185","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1038\/ncomms6370","article-title":"The MST1\/2-SAV1 complex of the Hippo pathway promotes ciliogenesis","volume":"5","author":"Kim","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2021.114423_b0190","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/cdd.2017.99","article-title":"The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway","volume":"24","author":"Furth","year":"2017","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2021.114423_b0195","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pathol.2019.01.001","article-title":"High Yes-associated protein 1 with concomitant negative LATS1\/2 expression is associated with poor prognosis of advanced gastric cancer","volume":"51","author":"Kim","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.bcp.2021.114423_b0200","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.3892\/mmr.2015.3231","article-title":"Yes-associated protein regulates the growth of human non-small cell lung cancer in response to matrix stiffness","volume":"11","author":"Yuan","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bcp.2021.114423_b0205","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","article-title":"Hippo-YAP\/TAZ signalling in organ regeneration and regenerative medicine","volume":"20","author":"Moya","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2021.114423_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060600","article-title":"Regulation of TEAD transcription factors in cancer biology","volume":"8","author":"Huh","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2021.114423_b0215","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.30278","article-title":"SAV1 promotes Hippo kinase activation through antagonizing the PP2A phosphatase STRIPAK","volume":"6","author":"Bae","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.bcp.2021.114423_b0220","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12351","article-title":"SAV1 represses the development of human colorectal cancer by regulating the Akt-mTOR pathway in a YAP-dependent manner","volume":"50","author":"Jiang","year":"2017","journal-title":"Cell Prolif."},{"key":"10.1016\/j.bcp.2021.114423_b0225","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/s41467-019-09233-7","article-title":"MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression","volume":"10","author":"Jiang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2021.114423_b0230","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41419-019-1560-y","article-title":"Alginate oligosaccharide attenuates \u03b12,6-sialylation modification to inhibit prostate cancer cell growth via the Hippo\/YAP pathway","volume":"10","author":"Han","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2021.114423_b0235","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1034\/j.1600-0463.2003.1110601.x","article-title":"Mutational analysis of salvador gene in human carcinomas","volume":"111","author":"Yoo","year":"2003","journal-title":"APMIS"},{"key":"10.1016\/j.bcp.2021.114423_b0240","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/path.4706","article-title":"Kidney-specific knockout of Sav1 in the mouse promotes hyperproliferation of renal tubular epithelium through suppression of the Hippo pathway","volume":"239","author":"Kai","year":"2016","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcp.2021.114423_b0245","doi-asserted-by":"crossref","first-page":"62953","DOI":"10.18632\/oncotarget.17972","article-title":"Protein salvador homolog 1 acts as a tumor suppressor and is modulated by hypermethylation in pancreatic ductal adenocarcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2021.114423_b0250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-4939-8910-2_18","article-title":"Structural and biochemical analyses of the core components of the hippo pathway","volume":"1893","author":"Ni","year":"2019","journal-title":"Methods Mol. Biol. (Clifton, NJ)."},{"key":"10.1016\/j.bcp.2021.114423_b0255","doi-asserted-by":"crossref","first-page":"584","DOI":"10.5483\/BMBRep.2011.44.9.584","article-title":"Phosphorylation of SAV1 by mammalian ste20-like kinase promotes cell death","volume":"44","author":"Park","year":"2011","journal-title":"BMB Rep."},{"key":"10.1016\/j.bcp.2021.114423_b0260","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/13543776.2018.1549226","article-title":"Hippo pathway inhibition by blocking the YAP\/TAZ-TEAD interface: a patent review","volume":"28","author":"Crawford","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2021.114423_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/jca.27472","article-title":"The efficiency of verteporfin as a therapeutic option in pre-clinical models of melanoma","volume":"10","author":"Lui","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.bcp.2021.114423_b0270","doi-asserted-by":"crossref","first-page":"32779","DOI":"10.1038\/srep32779","article-title":"Triptonide effectively inhibits Wnt\/\u03b2-catenin signaling via C-terminal transactivation domain of \u03b2-catenin","volume":"6","author":"Chinison","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2021.114423_b0275","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcp.2016.11.024","article-title":"Targeting of multiple senescence-promoting genes and signaling pathways by triptonide induces complete senescence of acute myeloid leukemia cells","volume":"126","author":"Pan","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114423_b0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxlet.2017.06.010","article-title":"Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway","volume":"278","author":"Yang","year":"2017","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bcp.2021.114423_b0285","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejphar.2017.11.019","article-title":"Triptonide potently suppresses pancreatic cancer cell-mediated vasculogenic mimicry by inhibiting expression of VE-cadherin and chemokine ligand 2 genes","volume":"818","author":"Han","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114423_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2019.01.002","article-title":"Triptonide inhibits lung cancer cell tumorigenicity by selectively attenuating the Shh-Gli1 signaling pathway","volume":"365","author":"Zhang","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114423_b0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114870","article-title":"Triptonide effectively suppresses gastric tumor growth and metastasis through inhibition of the oncogenic Notch1 and NF-\u03baB signaling pathways","volume":"388","author":"Xiang","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114423_b0300","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bcp.2019.05.010","article-title":"Selective activation of tumor-suppressive MAPKP signaling pathway by triptonide effectively inhibits pancreatic cancer cell tumorigenicity and tumor growth","volume":"166","author":"Zhang","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114423_b0305","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1038\/s41418-020-0514-3","article-title":"The lipogenic LXR-SREBF1 signaling pathway controls cancer cell DNA repair and apoptosis and is a vulnerable point of malignant tumors for cancer therapy","volume":"27","author":"Yang","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcp.2021.114423_b0310","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/path.1711720409","article-title":"Classification of CEA-related positivity in primary and metastatic malignant melanoma","volume":"172","author":"Sanders","year":"1994","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcp.2021.114423_b0315","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1034\/j.1600-0560.2000.027007351.x","article-title":"The carcinoembryonic antigen (CEA) family (CD66) expressed in melanocytic naevi is not expressed in blue naevuscell naevi in dendritic type","volume":"27","author":"Egawa","year":"2000","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.bcp.2021.114423_b0320","first-page":"3083","article-title":"Does human melanoma express carcinoembryonic antigen?","volume":"20","author":"Ravindranath","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2021.114423_b0325","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","article-title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis","volume":"32","author":"Beauchemin","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bcp.2021.114423_b0330","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fcell.2019.00156","article-title":"Safety considerations in the development of hippo pathway inhibitors in cancers","volume":"7","author":"Kakiuchi-Kiyota","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2021.114423_b0335","article-title":"Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy","volume":"1873","author":"Reggiani","year":"2020","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2021.114423_b0340","doi-asserted-by":"crossref","DOI":"10.1242\/dev.167106","article-title":"Hippo signalling during development","volume":"146","author":"Davis","year":"2019","journal-title":"Development (Cambridge, England)"},{"key":"10.1016\/j.bcp.2021.114423_b0345","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1038\/s41388-019-0924-1","article-title":"The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells","volume":"38","author":"Gobbi","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2021.114423_b0350","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1111\/febs.15017","article-title":"The Hippo and Wnt signalling pathways: crosstalk during neoplastic progression in gastrointestinal tissue","volume":"286","author":"Li","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.bcp.2021.114423_b0355","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122131","article-title":"Hippo pathway and YAP signaling alterations in squamous cancer of the head and neck","volume":"8","author":"Santos-de-Frutos","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2021.114423_b0360","first-page":"610","article-title":"The HIPPO pathway in gynecological malignancies","volume":"10","author":"Wang","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bcp.2021.114423_b0365","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ceb.2019.07.006","article-title":"Role of the transcriptional coactivators YAP\/TAZ in liver cancer","volume":"61","author":"Zhang","year":"2019","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bcp.2021.114423_b0370","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12935-019-0898-7","article-title":"YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway","volume":"19","author":"Zhou","year":"2019","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2021.114423_b0375","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1038\/s41388-019-0858-7","article-title":"The MRVI1-AS1\/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway","volume":"38","author":"Zhu","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2021.114423_b0380","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fct.2013.03.044","article-title":"Acute and subacute toxicity studies on triptolide and triptolide-loaded polymeric micelles following intravenous administration in rodents","volume":"57","author":"Xu","year":"2013","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.bcp.2021.114423_b0385","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jep.2015.01.004","article-title":"Investigation of the active components in Tripterygium wilfordii leading to its acute hepatotoxicty and nephrotoxicity","volume":"162","author":"Li","year":"2015","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bcp.2021.114423_b0390","first-page":"622","article-title":"Targets and molecular mechanisms of triptolide in cancer therapy","volume":"26","author":"Meng","year":"2014","journal-title":"Chin. J. Cancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221000198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221000198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:21:59Z","timestamp":1757769719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":78,"alternative-id":["S0006295221000198"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114423","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of the tumor suppressive Hippo pathway by triptonide as a new strategy to potently inhibit aggressive melanoma cell metastasis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114423"}}